|
MLH3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62969637784727E-12 |
| Normal-vs-Stage2 |
2.78120000363202E-08 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
3.615600E-02 |
| Stage1-vs-Stage3 |
3.787800E-01 |
| Stage1-vs-Stage4 |
1.939910E-02 |
| Stage2-vs-Stage3 |
2.415600E-02 |
| Stage2-vs-Stage4 |
1.080120E-03 |
| Stage3-vs-Stage4 |
1.215020E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
9.02650000300653E-08 |
| Normal-vs-Asian |
4.22994972382185E-14 |
| Caucasian-vs-AfricanAmerican |
4.688600E-01 |
| Caucasian-vs-Asian |
7.962800E-01 |
| AfricanAmerican-vs-Asian |
5.996600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.1094237467878E-15 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
5.788600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.32827124036339E-15 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62736490949555E-12 |
| Normal-vs-Age(81-100Yrs) |
3.20720000002161E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.737000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.378400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.916800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.675200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.130000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.576800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.89089999999404E-05 |
| Classical-VS-Follicular |
5.479500E-03 |
| Classical-VS-Other |
6.400400E-01 |
| Classical-VS-Normal |
1.88737914186277E-14 |
| Tall-VS-Follicular |
1.93939999948434E-07 |
| Tall-VS-Other |
1.723230E-01 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
2.172000E-01 |
| Follicular-VS-Normal |
1.23180021738278E-10 |
| Other-VS-Normal |
9.96109999999994E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
4.44089209850063E-16 |
| N0-vs-N1 |
2.774200E-02 |
|
|
